So far, clinical trials aiming to improve glutathione contents in ALS by supplementation have been ineffective [106,107], as well as clinical trials targeting Nrf2 activating substances [102,103,104,105,113]. Here, NFE2L2 is linked to amyotrophic lateral sclerosis.